ストックスクリーナーアプリを入手
3.47
0.57%
-0.02
アフターアワーズ：
3.49
0.02
+0.58%
前日終値:
$3.49
開ける：
$3.48
24時間の取引高:
130.87K
Relative Volume:
0.47
時価総額：
$51.42M
収益：
$6.66M
当期純損益:
$-25.52M
株価収益率:
-2.8678
EPS:
-1.21
ネットキャッシュフロー:
$-28.98M
1週間 パフォーマンス:
+7.10%
1か月 パフォーマンス:
-38.12%
6か月 パフォーマンス:
-34.59%
1年 パフォーマンス:
-59.50%
1日の値動き範囲:
$3.395
$3.60
1週間の範囲:
$3.20
$3.6915
52週間の値動き範囲:
$2.64
$14.20
Veru Inc Stock (VERU) Company Profile
VERU を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
3.47 | 51.42M | 6.66M | -25.52M | -28.98M | -1.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.18 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.65 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.20 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
708.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.91 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-14 | 開始されました | B. Riley Securities | Buy |
| 2024-03-28 | 開始されました | Raymond James | Outperform |
| 2023-06-07 | アップグレード | Jefferies | Underperform → Hold |
| 2021-04-13 | 開始されました | Jefferies | Buy |
| 2021-02-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-20 | 開始されました | Oppenheimer | Outperform |
| 2018-07-03 | 開始されました | Maxim Group | Buy |
すべてを表示
Veru Inc (VERU) 最新ニュース
Raymond James Financial Cuts Veru (NASDAQ:VERU) Price Target to $20.00 - MarketBeat
Veru (NASDAQ:VERU) Issues Quarterly Earnings Results - MarketBeat
Is Veru Inc.’s ROE strong enoughMarket Activity Summary & Momentum Based Trading Signals - thegnnews.com
Veru (NASDAQ:VERU) Sets New 52-Week LowWhat's Next? - MarketBeat
Price Floor Holding on Veru Inc. — Rebound PossibleJuly 2025 Recap & Technical Entry and Exit Alerts - newsyoung.net
Veru Announces Novel Modified-Release Oral Formulation for Enobosarm - Yahoo Finance
Veru Inc. Charts Flash Early Recovery SignalsWeekly Volume Report & Low Risk High Win Rate Picks - newsyoung.net
Raymond James Keeps Their Buy Rating on Veru (VERU) - The Globe and Mail
Veru (STU:FMW0) Tariff Resilience Score : 5/10 (As of Aug. 14, 2025) - GuruFocus
Will Veru Inc. rebound enough to break evenQuarterly Profit Report & Fast Gain Swing Trade Alerts - Newser
Is Veru Inc. a strong growth stockMarket Volume Report & Short-Term Swing Trade Alerts - news-j.co.kr
What indicators show strength in Veru Inc.Options Play & Scalable Portfolio Growth Ideas - Newser
Why Veru Inc. stock attracts strong analyst attentionEarnings Beat & Safe Entry Zone Identification - Newser
Veru Inc. stock prediction for this weekMarket Risk Summary & Technical Buy Zone Confirmations - Newser
How sentiment analysis helps forecast Veru Inc.Trade Risk Summary & Weekly High Potential Stock Alerts - Newser
Top chart patterns to watch in Veru Inc.2025 Analyst Calls & Precise Buy Zone Tips - Newser
Is Veru Inc. meeting your algorithmic filter criteriaMarket Rally & Weekly Market Pulse Updates - Newser
Veru stock price target raised to $25 from $4 at Oppenheimer on GLP-1 muscle loss drug - Investing.com Australia
Raymond James Maintains Veru Inc(VERU.US) With Buy Rating, Raises Target Price to $20 - 富途牛牛
Anchoring Your Portfolio: Is VERU Stock a Safe Harbor? - investchronicle.com
VERU Stock: Analyst Maintains Outperform Rating, Lowers Price Ta - GuruFocus
Veru (FRA:FMW0) Tariff Resilience Score : 5/10 (As of Aug. 13, 2025) - GuruFocus
Veru stock price target lowered to $20 at Raymond James on obesity drug - Investing.com Nigeria
Statistical indicators supporting Veru Inc.’s strengthRecession Risk & Daily Profit Maximizing Tips - Newser
Veru Inc (VERU) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Veru Inc. Reports Positive Results and Progress - TipRanks
Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress - GlobeNewswire
Full technical analysis of Veru Inc. stockTrade Ideas Based on Fundamental Metrics - Newser
Is Veru Inc. stock forming a triangle patternStocks with Highest Alpha - thegnnews.com
Veru Q3 2025 Earnings Call Transcript - MarketBeat
Transcript : Veru Inc., Q3 2025 Earnings Call, Aug 12, 2025 - MarketScreener
Veru's Q3 2025 Earnings Call: Unpacking Key Contradictions in Phase III Trial Costs and Enobosarm's Safety Profile - AInvest
VERU INC. SEC 10-Q Report - TradingView
Veru Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Veru Inc. Q3 2025 sees significant EPS miss - Investing.com
Veru Inc. (NASDAQ:VERU) Looks Inexpensive After Falling 40% But Perhaps Not Attractive Enough - 富途牛牛
Why Investors Shouldn't Be Surprised By Veru Inc.'s (NASDAQ:VERU) 40% Share Price Plunge - simplywall.st
Veru Implements 1-for-10 Reverse Stock Split - TipRanks
Veru Inc. Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress - TradingView
Veru Inc. (VERU): A High-Risk, High-Reward Biotech Play with a Turnaround Story - AInvest
Evaluating Veru Inc. with trendline analysisFree Swing Setup With Technical Confirmation - Newser
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology - BioSpace
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru's Enobosarm, Utilizing Laxxon's SPID®-Technology - Lelezard
Veru selects Laxxon’s SPID technology for modified-release enobosarm By Investing.com - Investing.com Nigeria
Veru selects Laxxon’s SPID technology for modified-release enobosarm - Investing.com
Laxxon Medical Announces Successful Product Development Milestone with Novel Oral Modified-Release Formulation of Veru’s Enobosarm, Utilizing Laxxon’s SPID®-Technology | FinancialContent - FinancialContent
Veru selects oral enobosarm formulation for development - The Pharma Letter
Veru Selects Novel Oral Formulation for Chronic Weight Loss Management Drug - MarketScreener
Veru selects modified release formulation for enobosarm weight drug - Investing.com
Veru selects modified release formulation for enobosarm weight drug By Investing.com - Investing.com UK
Veru Announces Selection of Novel Modified Release Oral - GlobeNewswire
Veru Inc (VERU) 財務データ
収益
当期純利益
現金流量
EPS
Veru Inc (VERU) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Rankowitz Michael L | Director |
Feb 19 '25 |
Buy |
0.58 |
54,721 |
31,919 |
250,000 |
0.95%
0.90%
大文字化:
|
ボリューム (24 時間):